%0 English Abstract
%T [Interpretation of the 2021 American Academy of Allergy, Asthma and Immunology expert consensus on the treatment of postinfectious olfactory dysfunction].
%A Han R
%A Meng C
%A Zhu D
%A Xiu Q
%J Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
%V 37
%N 2
%D Feb 2023
%M 36756819
暂无%R 10.13201/j.issn.2096-7993.2023.02.001
%X  Respiratory tract viruses are the second leading cause of olfactory dysfunction. Between 2019 to 2022, the world has been plagued by the problem of olfaction caused by the COVID-19. As we learn more about the impact of severe acute respiratory syndrome coronavirus 2（SARS-CoV-2）, with the recognition that olfactory dysfunction is a key symptom of this disease process, there is a greater need than ever for evidence-based management of postinfectious olfactory dysfunction（PIOD）. The Clinical Olfactory Working Group has proposed theconsensus on the roles of PIOD. This paper is the detailed interpretation of the consensus.<BR>摘要: 呼吸道病毒是临床上引起嗅觉功能障碍的第二大常见原因。2019-2022年间，全球一直经历着新冠疫情的困扰，疫情引发的嗅觉问题逐渐受到专家们的关注。随着我们对严重急性呼吸系统综合征冠状病毒（SARS-CoV-2）引发症状的了解不断深入，发现嗅觉障碍是该疾病进展中的重要一环，因而对于基于循证医学的病毒感染后失嗅（PIOD）的治疗方法是目前所亟需的。临床嗅觉工作组为此发表了一篇针对PIOD的治疗共识。本文特对该专家共识进行了解读。.